Posted by Generex on LinkedIn today Cases of #
Post# of 36536
(Total Views: 482)
Posted On: 12/16/2020 4:25:53 PM
Posted by Generex on LinkedIn today
Cases of #COVID-19 reinfection a mere 8 months after initial infection, in those who are thought to be otherwise healthy, are a major concern in control of the pandemic. At Generex, our ii-key vaccine technology, currently in testing, enables a potent response against select epitopes on #SARS-CoV-2 with the goal of providing long-term memory and immunity to COVID-19.
#COVID19 #biotech #Coronaviruscure #Coronavirusvaccine #Sarscov2 #Immunology #Immunotherapy #Tcells #Biotechnology #Clinicaltrial #Iikeypeptide #completevaccine
https://www.wsj.com/articles/the-pro-cyclist-...1606919308
Cases of #COVID-19 reinfection a mere 8 months after initial infection, in those who are thought to be otherwise healthy, are a major concern in control of the pandemic. At Generex, our ii-key vaccine technology, currently in testing, enables a potent response against select epitopes on #SARS-CoV-2 with the goal of providing long-term memory and immunity to COVID-19.
#COVID19 #biotech #Coronaviruscure #Coronavirusvaccine #Sarscov2 #Immunology #Immunotherapy #Tcells #Biotechnology #Clinicaltrial #Iikeypeptide #completevaccine
https://www.wsj.com/articles/the-pro-cyclist-...1606919308
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼